New drug application of Paimpril accepted by State Drug Administration


On May 26, Sino Biopharmaceutical issued an announcement saying that the anti-PD-1 monoclonal antibody drug Anike (generic name: Paimpril, R&D code: AK105) jointly developed and commercialized by the company and Akeso has its application accepted by the State Drug Administration of China.

It is used for the treatment of patients with relapsed or refractory Classical Hodgkin's Lymphoma.

Classical Hodgkin Lymphoma (cHL) is a B-cell lymphoma, and is also one of the most common malignancies among young people. It has a single modal age distribution in China with a peak at around 40 years of age .

cHL is one of the few tumors that can be cured, and the most common therapy is chemotherapy plus radiotherapy, with the 5-year survival rate of patients as high as over 80%.

Although the first-line chemotherapy has a high clinical cure rate, a considerable portion of patients are insensitive to chemotherapy and approximately 5% to 10% of patients do not respond to the initial treatment.


JD Health and AstraZeneca start strategic cooperation
Medical care , Pharmaceutical

China Isotope & Radiation Corporation and Bayer agree to introduce Xofigo into China
Pharmaceutical , Medical care

Xuanzhu Biopharm closes RMB 800 mln Series A
Pharmaceutical , PEVC

Anti-body R&D company Escugen closes Pre-A raising tens of millions in RMB
PEVC , Biotech , Pharmaceutical

China's first COVID-19 vaccine produced by insect cells obtained clinical trial approval
Pharmaceutical , Vaccine , Covid-19 , Biotech

D2M Biotherapeutics completes $10 million Pre-A round of financing
PEVC , Pharmaceutical , Biotech

China's first mRNA Covid-19 vaccine approved for clinical trials
Covid-19 , Biotechnology

Bio-Thera: BAT1308 injection received notification of clinical trial
Healthcare , Pharmaceutical

Maccura Biotechnology's new coronavirus detection product obtains registration certificate
Medical care , Pharmaceutical

Hengrui Medicine: Remazolam Tosylate for Injection Obtained Clinical Trial Notice
China SDG